Ashley Lawton Ph.D. has more than twenty years experience in business development and general management within the pharmaceutical and biotechnology industry. Through his roles at Eli Lilly Celltech RepliGen Genzyme and Phylos he has broad expertise in the development and commercialization of protein therapeutics.
Dr. Lawton is responsible for Business Development at GTC Biotherapeutics with a focus on developing the Follow-On Biologics business and the commercialization of internal early-stage research programs.
Dr. Lawton graduated from Southampton University UK with a Ph.D. in Biochemistry and a B.Sc. in Human Physiology and Biochemistry. More recently he graduated from Boston University with an MBA in General Management. |